Anatara Lifesciences Ltd (AU:ANR)
ASX:ANR
Top Page
Anatara Lifesciences Ltd
(Sydney:ANR)
Select Model
Select Model
Rating:40Underperform
Price Target:
AU$0.01
▲(0.00% Upside)
Action:DowngradedDate:02/28/26
The score is primarily held down by weak financial performance (persistent losses, negative margins, worsening cash burn, and shrinking equity). Technical indicators also reflect strong downside pressure, while valuation inputs are limited by negative earnings and no stated dividend yield.
Positive Factors
Focused pipeline (GaRP)
A focused lead program (GaRP) targeting gastrointestinal health gives the company a clear development path. Ongoing clinical/validation and regulatory work indicate methodical progression toward market entry, which supports durable value creation if trials and approvals advance.
Negative Factors
Negative gross profit and margins
Persistently negative gross profit and deeply negative net margins show core costs exceed revenue, indicating the current business model is not yet economically sustainable. Without structural margin improvement, losses will continue to erode equity and limit strategic options.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused pipeline (GaRP)
A focused lead program (GaRP) targeting gastrointestinal health gives the company a clear development path. Ongoing clinical/validation and regulatory work indicate methodical progression toward market entry, which supports durable value creation if trials and approvals advance.
Read all positive factors
Anatara Lifesciences Ltd (ANR) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.84M
Dividend YieldN/A
Average Volume (3M)759.89K
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue GrowthN/A
EPS Growth1.03%
CountryAU
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding315,950,780
10 Day Avg. Volume1,527,300
30 Day Avg. Volume759,886
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)1.91
Price to Sales (P/S)1.06
P/FCF Ratio-0.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Anatara Lifesciences Ltd Business Overview & Revenue Model
Company Description
Anatara Lifesciences Limited engages in the research, development, and commercializing of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulatio...
How the Company Makes Money
Anatara Lifesciences Ltd generates revenue through the development and commercialization of its proprietary health solutions. The company earns money by licensing its technologies and products to pharmaceutical and biotech companies, which in turn...
Anatara Lifesciences Ltd Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
33
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 223.10K | 969.46K | 644.03K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -122.25K | -633.97K | -748.91K | -24.76K | -24.68K | -6.26K |
| EBITDA | -1.09M | -1.96M | -1.46M | -3.21M | -2.97M | -3.01M |
| Net Income | -911.79K | -1.95M | -1.45M | -2.02M | -2.53M | -2.00M |
Balance Sheet | ||||||
| Total Assets | 1.33M | 1.15M | 1.67M | 1.42M | 1.77M | 4.33M |
| Cash, Cash Equivalents and Short-Term Investments | 1.09M | 101.36K | 982.11K | 401.18K | 1.17M | 3.43M |
| Total Debt | 0.00 | 407.42K | 0.00 | 0.00 | 65.80K | 79.92K |
| Total Liabilities | 195.91K | 612.42K | 306.85K | 494.83K | 403.35K | 496.67K |
| Stockholders Equity | 1.13M | 535.97K | 1.36M | 924.54K | 1.36M | 3.83M |
Cash Flow | ||||||
| Free Cash Flow | -404.20K | -2.27M | -1.25M | -2.26M | -2.24M | -2.10M |
| Operating Cash Flow | -404.19K | -2.27M | -1.25M | -2.26M | -2.23M | -2.10M |
| Investing Cash Flow | 50.00K | 0.00 | 50.00K | -1.73K | -56.56K | -3.98K |
| Financing Cash Flow | 1.07M | 1.39M | 1.83M | 1.49M | -22.44K | 2.85M |
Anatara Lifesciences Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$33.06M | -6.66 | -370.40% | ― | 306.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$10.20M | -0.48 | 1068.18% | ― | ― | 31.87% | |
42 Neutral | AU$9.43M | -1.00 | -218.76% | ― | ― | ― | |
40 Underperform | AU$2.84M | -1.64 | -109.45% | ― | ― | 1.03% | |
40 Underperform | AU$35.68M | -10.60 | -142.30% | ― | 110.44% | 35.90% | |
40 Underperform | AU$2.17M | -4.31 | -32.19% | ― | ― | 46.43% |
* Healthcare Sector Average
AU:ANR
Anatara Lifesciences Ltd
0.01
>-0.01
-9.09%
AU:ADO
AnteoTech Ltd
0.01
<0.01
20.00%
AU:CMB
Regeneus Ltd.
0.35
0.06
23.21%
AU:AVE
Avecho Biotechnology Limited
0.01
0.00
0.00%
AU:1AD
AdAlta Ltd.
―
―
―
AU:HXL
Hexima Ltd
0.01
0.00
0.00%
Anatara Lifesciences Ltd Corporate Events
Anatara Lifesciences Seeks ASX Quotation for 2.36m New Shares
Feb 25, 2026
Anatara Lifesciences has applied for quotation on the ASX of 2,360,426 new ordinary fully paid shares. The securities, issued on February 25, 2026 following the exercise or conversion of existing options or other convertible instruments, will incr...
Anatara Lifesciences Converts 2.36 Million Performance Rights Into Ordinary Shares
Feb 25, 2026
Anatara Lifesciences has converted 2,360,426 ANRAR performance rights into an equivalent number of ordinary shares for an employee, following the satisfaction of vesting conditions and the employee’s election to receive the shares. The compa...
Anatara Lifesciences Narrows Half-Year Loss as Revenue Slides
Feb 25, 2026
Anatara Lifesciences reported a sharp 66% fall in revenue from ordinary activities to $177,564 for the half-year ended 31 December 2025. The company’s net loss after tax attributable to members narrowed by 56% to $514,975, underscoring ongoi...
Anatara Flags Promising Anti-Obesity Data as Capital Raise Bolsters Pipeline Plans
Jan 30, 2026
Anatara Lifesciences reported that interim pre-clinical data from its Anti-Obesity Project at the University of Newcastle identified a lead candidate compound, AOC, which showed statistically significant effects in attenuating post-semaglutide wei...
Anatara Lifesciences Reports Promising Results in Anti-Obesity Project
Dec 17, 2025
Anatara Lifesciences Ltd has reported promising pre-clinical results for its Anti-Obesity Project, with the candidate compound AOC showing significant potential in managing weight reduction and controlling weight gain after cessation of weight los...
Anatara Lifesciences Announces Director’s Interest Change
Dec 11, 2025
Anatara Lifesciences Limited has announced a change in the director’s interest notice concerning Dr. David Brookes. The company disclosed that Dr. Brookes has disposed of 932,143 unlisted options, with no new securities acquired. This change...
Anatara Lifesciences Announces Cessation of Securities
Dec 11, 2025
Anatara Lifesciences Ltd announced the cessation of 27,749,784 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could infl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.